Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
Conditions
Interventions
Pembrolizumab
Intismeran autogene
+1 more
Locations
106
United States
USC/Norris Comprehensive Cancer Center ( Site 1112)
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian ( Site 1122)
Newport Beach, California, United States
Stanford Cancer Center ( Site 1109)
Palo Alto, California, United States
University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 1103)
Sacramento, California, United States
Winship Cancer Institute, Emory University ( Site 1151)
Atlanta, Georgia, United States
University of Iowa-Holden Comprehensive Cancer Center ( Site 1118)
Iowa City, Iowa, United States
Start Date
April 18, 2024
Primary Completion Date
March 5, 2026
Completion Date
March 5, 2026
Last Updated
March 27, 2026
NCT07404605
NCT04099290
NCT06912087
NCT04429542
NCT04564989
NCT05955924
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions